Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, central nervous system, anti-infectives, epilepsy, allergy and vitamins, and minerals and supplements, as well as pain care and nutritional health under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Glimepiride, Cetapin, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors. It also exports its products to approximately 35 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.

Revenue projections:

Revenue projections for SANOFI
Revenue projections for SANOFI

Investors may be wary of SANOFI as its revenues are expected to fall below the prior year's levels. A revenue decrease often leads to concerns about profitability, as it is likely to affect the company's bottom line, prompting investors to take a more cautious approach.

Financial Ratios:

currentRatio 0.000000
forwardPE 24.090628
debtToEquity 2.672000
earningsGrowth -0.076000
revenueGrowth -0.093000
grossMargins 0.506440
operatingMargins 0.263150
trailingEps 154.640000
forwardEps 203.770000

Sanofi India Limited's Forward PE is in a favorable range, suggesting the stock is reasonably priced relative to its earnings. This indicates the stock is not overpriced, providing room for potential growth and making it an attractive option for investors looking for solid value and future upside.
SANOFI's low earnings and revenue growth suggest that the company may face shrinking profits. This could indicate underlying financial challenges, making it difficult for SANOFI to sustain its current profitability.
SANOFI's positive gross and operating margins reflect strong profitability and operational efficiency. These metrics indicate the company's ability to control costs while maintaining healthy revenue, contributing to its solid financial performance.
SANOFI's forward EPS is greater than its trailing EPS, indicating that the company is expected to deliver higher profitability this year. This suggests that SANOFI is projected to improve its earnings, reflecting positive growth compared to last year's financial performance.

Price projections:

Price projections for SANOFI
Price projections for SANOFI

Price projections for SANOFI have been steadily revised downward over time, indicating growing concerns about the company's future performance. This downward trend reflects reduced optimism among analysts regarding SANOFI's ability to meet previous expectations.

Recommendation changes over time:

Recommendations trend for SANOFI
Recommendations trend for SANOFI


With analysts showing a buy bias for Sanofi India Limited, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning Sanofi India Limited as a safe and profitable place for investors to allocate their funds and seek growth.